JUN 3 0 2009 W

UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sudeepta AGGARWAL, et al.

Application Serial No. 10/533,069

Examiner: Basi, Nirmal Singh

Art Unit: 1646

Confirmation No. 5360

Filed: January 3, 2007 Attorney's Docket No. GNE-0269 R1

For: COMPOSITIONS AND METHODS FOR) Customer No. 77845

THE TREATMENT OF IMMUNE RELATED DISEASES

EXPRESS MAIL LABEL NO. $\underline{\text{EM } 305\ 115\ 666\ US}$ ON JUNE 30, 2009

AMENDMENT/RESPONSE TO OFFICE ACTION

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action mailed on April 1, 2009, in connection with the above-referenced application (Paper No./Mail Date 20090328), please enter the following amendments and consider the following remarks. Applicants further submit herewith a Substitute Specification in compliance with 37 C.F.R. §1.125 (including both a Marked-Up Copy and a Clean Copy) and a statement that the accompanying substitute specification includes no new matter. This Response is timely filed within the three-month shorten statutory time period set for the response.

Enclosed is an Information Disclosure Statement providing a copy of the article by Molloy et al.

Amendments to the Specification begin on page $\underline{2}$ of this paper.

Amendments to the Drawings begin on page 3 of this paper.

Amendments to the Claims begin on page 4 of this paper.

Remarks/Arguments begin on page 6 of this paper.